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Peroxisome proliferator activated receptor gamma 2 (PPARg2) is the nutritionally regulated isoform of PPARg.
Ablation of PPARg2 in the ob/ob background, PPARg2
 /  Lep
ob/Lep
ob (POKO mouse), resulted in decreased fat mass,
severe insulin resistance, b-cell failure, and dyslipidaemia. Our results indicate that the PPARg2 isoform plays an
important role, mediating adipose tissue expansion in response to positive energy balance. Lipidomic analyses suggest
that PPARg2 plays an important antilipotoxic role when induced ectopically in liver and muscle by facilitating
deposition of fat as relatively harmless triacylglycerol species and thus preventing accumulation of reactive lipid
species. Our data also indicate that PPARg2 may be required for the b-cell hypertrophic adaptive response to insulin
resistance. In summary, the PPARg2 isoform prevents lipotoxicity by (a) promoting adipose tissue expansion, (b)
increasing the lipid-buffering capacity of peripheral organs, and (c) facilitating the adaptive proliferative response of b-
cells to insulin resistance.
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Introduction
An adipocentric view of the Metabolic Syndrome (MS)
considers obesity as the major factor leading to insulin
resistance in peripheral metabolic tissues. However, the link
between obesity and insulin resistance is complex, as
indicated by the fact that some extremely obese people are
glucose tolerant, while others with a mild degree of obesity
develop severe insulin resistance and diabetes. This suggests
that the absolute amount of fat stored may not be the most
important factor determining the relationship between
obesity and insulin resistance. Recent work showing the
complexity of the molecular mechanisms controlling adipo-
genesis [1,2] suggests that adipose tissue expandability may be
an important factor linking obesity, insulin resistance, and
associated comorbidities.
There are two mechanisms that have been proposed to
explain how expansion of the adipose tissue stores affects
insulin sensitivity. One mechanism suggests that increased
adiposity induces a chronic inﬂammatory state characterized
by increased cytokine production by adipocytes and/or from
macrophages inﬁltrating adipose tissue. Cytokines produced
by these adipocytes or macrophages may directly antagonise
insulin signalling [3,4]. A second nonexclusive hypothesis is
lipotoxicity. The lipotoxic hypothesis states that if the
amount of fuel entering a tissue exceeds its oxidative or
storage capacity, toxic metabolites that inhibit insulin action
are formed [5–8]. Of particular relevance to this article, lipid
metabolites, such as ceramides and diacylglycerol (DAG) or
reactive oxygen species generated from hyperactive oxidative
pathways, have been shown to inhibit insulin signalling and to
induce apoptosis [9–11].
The nuclear receptor peroxisome proliferator activated
receptor gamma (PPARg) is critically required for adipo-
genesis and insulin sensitivity [12–15]. There are two PPARg
isoforms, PPARg1 and PPARg2. PPARg1 is expressed in many
tissues and cell types, including white and brown adipose
tissue, skeletal muscle, liver, pancreatic b-cells, macrophages,
colon, bone, and placenta [16]. Under physiological con-
ditions, expression of PPARg2, the other splice variant, is
restricted to white and brown adipose tissue [16,17]. In
adipose tissue PPARg is the key regulator of adipogenesis.
PPARg2 is the more adipogenic PPARg isoform in vitro, it is
also the isoform regulated transcriptionally by nutrition [17–
20]. Although under physiological conditions expression of
PPARg2 is limited to adipose tissues, we have shown that
PPARg2 is ectopically induced in liver and skeletal muscle in
response to overnutrition or genetic obesity [2,18]. De novo
expression of PPARg2 in liver and muscle in obesity suggests
that PPARg2 may have a role in insulin resistance and
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metabolic roles for the speciﬁc isoforms of PPARg has been
carried out, with the studies so far focusing almost exclusively
on adipose tissue [2,13,21,22]. PPARg (both isoforms) dele-
tions have been generated in most major metabolic tissues.
Liver-speciﬁc deletion of both PPARg isoforms caused an
impairment in insulin sensitivity, particularly when chal-
lenged by different genetic backgrounds (lipoatrophic or
leptin-deﬁciency) [23,24]. The effect of ablating both PPARg
isoforms in muscle produced controversial results, with two
groups reporting different effects on insulin sensitivity
[25,26]. The role of PPARg in pancreatic b-cells is unclear,
primarily due to its low expression under physiological
conditions [27–29] and secondly because ablation of both
PPARg isoforms in b-cells did not result in a metabolic
phenotype. However PPARg may play a role in b-cell
hyperplasia in response to insulin resistance, an idea
supported by the fact that mice that lack PPARg in b-cells
do not expand their b-cells mass in response to a high-fat diet
[30]. More recently, it has been shown that heterozygous
PPARg-deﬁcient mice develop impaired insulin secretion,
which is associated with increased islet triacylglycerol (TAG)
content [31].
Here we investigate the physiological relevance of PPARg2
under conditions of positive energy balance by ablating
PPARg2 in ob/ob mice. We use a new approach that integrates
traditional physiological phenotyping with advanced lipido-
mic technology and transcriptomics. Our results indicate that
in the context of positive energy balance, the absence of
PPARg2 results in a major metabolic failure. Furthermore, we
provide evidence that control of adipose tissue expansion by
PPARg2 may be an important variable linking positive energy
balance to its metabolic complications including insulin
resistance, b-cell failure, and dyslipidaemia. Similarly, our
lipidomic results indicate that induction of PPARg2 in
nonadipose tissues should be considered as a physiological
adaptation that prevents the toxic effects produced by excess
nutrients. This antilipotoxic effect of PPARg2 is achieved by
increasing the lipid-buffering capacity of peripheral organs
and facilitating b-cell hyperplasia in response to insulin
resistance.
Results
Ablation of PPARg2 in Ob/Ob Mice (POKO Mouse)
Prevents Adipose Tissue Expansion in Response to
Positive Energy Balance
PPARg2
 /  Lep
ob/Lep
ob mice with genetic ablation of the
PPARg2 isoform on the obese hyperphagic ob/ob background
(POKO) were generated. Matings of PPARg2
þ/  Lep
ob/Lep
þ
mice followed the expected Mendelian distribution (Fisher’s
test ¼ 0.074 and 0.135 for males and females, respectively).
PPARg1 gene expression in white adipose tissue (WAT) from
ﬁve-week-old POKO mice was similar to PPARg2 KO mice
and was not signiﬁcantly different from wild-type (WT) mice
(Figure S1).
Figure 1A shows growth curves for male and female mice of
four genotypes (WT, PPARg2 KO, ob/ob, and POKO mice)
over a 12-week period. At birth, the body weight of male and
female POKO mice was indistinguishable from other geno-
types (unpublished data). The ob/ob mice quickly became
heavier than their WT littermates, with signiﬁcantly elevated
body weight by four and six weeks of age in female and male
mice, respectively. However, the POKO mice did not become
obese, and their body weight remained close to WT and
PPARg2 KO body weights mice during the 12-week study.
POKO mice were as hyperphagic (Figure 1B) as the ob/ob
mice but drank far more water compared with ob/ob
littermates (81.85 6 15.14 versus 9.05 6 2.32 ml/70 h, p ,
0.01, female POKO versus ob/ob, n¼4 at 20 wk) (Figure S2A).
Dual-energy X-ray absorptiometry analysis at 20 wk (Figure
1C) conﬁrmed that female POKO mice had slightly increased
fat content (4%) compared to WT and PPARg2 KO mice, but
signiﬁcantly reduced fat mass compared to the 40% increase
observed in ob/ob mice. At the age of 20 wk, POKO and ob/ob
mice had a trend to a decreased total locomotor activity
during dark and light cycles compared with the WT and
PPARg2 KO mice over the 72-h period. However POKO had
similar total locomotor activity compared with ob/ob mice
(Figure S2B).
At six weeks of age, female POKO mice consumed a similar
amount of oxygen as ob/ob mice (vO2 ¼ 25.06 6 0.89 versus
23.10 6 0.99 ml/kg bodyweight
0.75/min, p¼0.07 POKO versus
ob/ob, n ¼ 6–8) showing a lower respiratory exchange ratio
(0.916 6 0.011 versus 0.952 6 0.007, p ¼ 0.01, female POKO
versus ob/ob) in the fed state, but similar respiratory
exchange ratio in the fasted state (0.73 6 0.014 versus 0.75
6 0.018, p-value ¼ 0.59 POKO versus ob/ob mice). Water
intake was already signiﬁcantly increased in POKO compared
to ob/ob mice (13.59 6 1.88 versus 8.15 6 0.89 ml/d, p-value ,
0.05, POKO versus ob/ob). Furthermore, levels of glucose in
urine were higher in POKO mice compared with ob/ob mice
(403.4 6 49.2 versus 34.13 6 13.5 mMol/l, POKO versus ob/ob
mice, p-value¼0.001), showing an energy loss of 15.43 6 3.06
kJ/d through urine compared with 0.70 6 0.19 kJ/d in ob/ob
mice. At this age, POKO mice showed similar locomotor
activity compared with the ob/ob mice during the day, but
increased locomotor activity during the night (Figure S2C).
Histomorphometric analysis of adipose tissue from 16-wk-
old male mice revealed that POKO mice had fewer small
adipocytes than the ob/ob mice (Figure 1D and 1E). This
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Author Summary
It is known that obesity is linked to type 2 diabetes, however how
obesity causes insulin resistance and diabetes is not well under-
stood. Some extremely obese people are not diabetic, while other
less obese people develop severe insulin resistance and diabetes.
We believe diabetes occurs when adipose tissue becomes ‘‘full,’’
and fat overflows into other organs such as liver, pancreas, and
muscle, causing insulin resistance and diabetes. Peroxisome
proliferator activated receptor gamma (PPARg) is essential for the
development of adipose tissue and control of insulin sensitivity.
PPARg2 is the isoform of PPARg regulated by nutrition. Here we
investigate the role of PPARg2 under conditions of excess nutrients
by removing the PPARg2 isoform in genetically obese mice, the
POKO mouse. We report that removing PPARg2 decreases adipose
tissue’s capacity to expand and prevents the mouse from making as
much fat as a normal obese mouse, despite eating similarly. Our
studies suggest that PPARg plays an important antitoxic role when it
is induced in liver, muscle, and beta cells by facilitating deposition of
fat as relatively harmless lipids and thus prevents accumulation of
toxic lipid species. We also show that PPARg2 may be involved in
the adaptive response of beta cells to insulin resistance.analysis of adipocyte size suggests that ablation of PPARg2 in
the ob/ob background impairs the potential for adipocyte
recruitment.
Early Insulin Resistance in POKO Mice Independent of
Body Weight
As expected the reduced adipose tissue expandability of
the POKO mouse was associated with severe insulin resist-
ance. Surprisingly insulin resistance developed very early in
life with elevated insulin levels and blood glucose compared
to ob/ob mice (Table 1). We investigated whether peripheral
insulin resistance and/or a severe defect in insulin secretion
may cause hyperglycaemia in the POKO mouse. No differ-
ences in plasma glucose levels were detected three to ﬁve days
after birth amongst the four genotypes for both genders
(unpublished data). At weaning (three weeks of age) total
Figure 1. Physiological Characterisation of POKO Mouse
(A) Body weights (black circles, WT; black squares, ob/ob; white circles, PPARg2 KO; white squares, POKO) are shown for males (left) or females (right)( n
¼ 5–12). *, p , 0.05 POKO versus ob/ob and §, p , 0.01 POKO versus WT.
(B) Food intake from 20-wk-old female mice (n ¼ 4) is shown.
(C) Body composition analysis from 20-wk-old females is shown: WT, ob/ob, PPARg2 KO, and POKO mice fed chow diet mice (n¼4–7). *, p , 0.05 POKO
versus WT and ###, p , 0.001 POKO versus ob/ob.
(D) Haematoxylin and eosin (H and E)-stained sections (103) from epididymal WAT from 16-wk-old male WT, ob/ob, and POKO mice.
(E) Percent relative cumulative frequency analysis (PRCF) from epididymal WAT adipocytes from 16-wk-old male WT, ob/ob, PPARg2 KO, and POKO
mice. (n ¼ 4–5).
doi:10.1371/journal.pgen.0030064.g001
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types, and blood glucose levels were similar in males and
females (Figure 2A). However, by the age of four weeks,
coincident with the change to a chow diet, male and female
POKO mice developed severe hyperglycaemia compared to
the other genotypes. Insulin plasma levels in the POKO mice
at four weeks of age were increased compared to ob/ob mice
(Table 1). Insulin resistance in POKO mice was conﬁrmed by
an insulin tolerance test (ITT) in four-week-old male and
female mice (Figure 2B). Furthermore insulin resistance in
adipose tissue was demonstrated by the extremely low levels
of glucose transporter4 (GLUT4) protein in POKO adipose
tissue when compared with GLUT4 levels in adipose tissue
from ob/ob mice (Figure S3). Of note, insulin resistance in the
POKO mice was associated with hypertriglyceridaemia as
early as four-weeks of age (Table 1).
Adult POKO Mice are Hyperglycaemic and Have Low
Plasma Insulin Levels
Given the early insulin resistance and hyperinsulinaemia in
the young POKO mice, we expected to see increased insulin
levels in mature POKO mice. At 16 weeks, male POKO mice
exhibited severe hyperglycaemia in the fasted and fed states
compared to littermate controls. Male POKO mice had
inappropriately low levels of insulin (Table 2). A similar,
but milder phenotype was also observed in POKO female
mice (unpublished data). Of note, adult ob/ob mice compen-
sated for their insulin resistance with increased insulin levels
(Table 2). POKO mice also had hypertriglyceridaemia when
compared to WT, ob/ob, or PPARg2 KO mice.
Impaired Beta-Cell Function in the POKO Mice
The inappropriately low insulin levels in the adult POKO
mice suggested a defect in b-cells. Insulin resistance in ob/ob
mice was compensated for by increasing pancreatic insulin
secretion, islet number, and size (Figure 3A). However,
despite being more insulin resistant than ob/ob mice, POKO
mice did not increase their b-cell mass, resulting in lower
plasma insulin levels than the ob/ob controls. Morphometric
analysis of pancreatic sections from 16-week-old male mice
conﬁrmed that the islet-to-pancreas volume ratios were
similar in the POKO, WT, and PPARg2 KO mice (0.023 6
0.005, 0.013 6 0.006, and 0.016 6 0.005, respectively) and
markedly increased in ob/ob mice (0.077 6 0.017, p , 0.01 ob/
ob versus POKO). Additionally, POKO mice had signiﬁcantly
decreased islet number and size (average area of islets POKO
¼18.40 6 2m m
2) compared to ob/ob mice (ob/ob¼61.59 6 8
mm
2). Insulin staining demonstrated that islets from POKO
mice contained fewer insulin-positive cells than islets from
ob/ob mice (Figure 3A). The normal cellular organization of
the islet, abundant b-cells (insulin staining) in the centre of
the islet and a rim of a-cells at the periphery (glucagon
staining), was retained in the insulin resistant ob/ob mice but
was disrupted in the islets of POKO mice (Figure 3A). Islets
from POKO mice had decreased number of insulin positive
b-cells when compared to islets from ob/ob mice and a
scattered pattern of a-cells, which are morphological changes
associated with islet remodelling in the context of b-cell
failure. Gene expression analysis of islets from 16-week-old
mice revealed decreased expression of pancreatic duodenal
homeobox-1, insulin receptor substrate 2, Glut2, and insulin
in islets from POKO mice when compared with those from
WT or ob/ob (Figure S4).
The changes seen in the b-cells of POKO mice were not the
result of an inherent failure of the b-cell to develop properly
as indicated by histological studies of neonatal pancreas (day
3 to day 5) (unpublished data) and four-week-old pancreas
(Figure 2C), showing no morphological differences in the size,
number, or insulin staining of islets from POKO mice when
compared to ob/ob controls.
Impaired Glucose-Stimulated Insulin Secretion in POKO
Mouse Islets
We measured glucose-stimulated insulin secretion in 16-
week-old female POKO mice and their ob/ob littermates.
Islets isolated from POKO mice were 30% smaller than those
from ob/ob mice. Moreover, whereas normal islets were pure
white with a smooth surface, islets from POKO mice were
gray; their surface was irregular and required less time for
collagenase digestion (only ten minutes instead of 30
minutes), suggesting that they were also more fragile.
Insulin content in islets from ob/ob mice was more than 30-
fold greater than in those from POKO mice (Figure 3B).
Insulin secretion from the islets of POKO mice was strikingly
impaired compared to those of ob/ob mice, even when
expressed relative to insulin content (Figure 3C). This was
observed under basal (1 mM glucose) and stimulated (16 mM
glucose, 16 mM glucose þ tolbutamide) release.
Table 1. Metabolic Parameters in Fed 4-Wk-Old Male and Female POKO, Ob/Ob, PPARg2 KO, and WT Mice
Mice Parameters Units WT PPARg2 KO Ob/ob POKO
Males 4 wk Glucose mMol/l 11.40 6 0.56 10.65 6 0.06 11.79 6 0.66 27.80 6 3.52*
Insulin lg/l 0.84 6 0.11 1.06 6 0.14 8.47 6 2.04 11.26 6 4.63
FFA mmol/l 0.63 6 0.06 0.84 6 0.05 0.43 6 0.03 1.06 6 0.09***
TAGs mmol/l 1.26 6 0.27 1.5 6 0.14 0.92 6 0.08 3.33 6 0.80**
Adiponectin lg/ml 19.17 6 1.33 7.36 6 1.57 25.34 6 2.27 7.42 6 1.16***
Females 4 wk Glucose mMol/l 9.07 6 0.39 9.56 6 1.04 10.50 6 0.68 20.87 6 1.79***
Insulin lg/l 0.83 6 0.15 0.78 6 0.12 16.98 6 4.26 19.56 6 2.98
FFA mmol/l 0.57 6 0.06 0.76 6 0.08 0.57 6 0.08 0.76 6 0.06
TAGs mmol/l 1.09 6 0.09 1.49 6 0.13 1.11 6 0.13 4.51 6 0.69***
Adiponectin lg/ml 28.41 6 2.38 7.71 6 0.07 38.12 6 2.87 8.49 6 2.10***
Values are mean 6 standard error of mean. n ¼ 6/9. *, p , 0.05; **, p , 0.01; and ***, p , 0.001 POKO versus ob/ob.
FFA, free fatty acid.
doi:10.1371/journal.pgen.0030064.t001
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PPAR gamma 2 and LipotoxicityDecreased Steatosis in POKO Mice Compared to Ob/Ob
Mice
As expected, the POKO mice had increased hepatic fat
deposition compared to WT and PPARg2 KO mice (Table S1),
but surprisingly the POKO mouse had much milder hep-
atosteatosis than the ob/ob mouse (Figure 3D), suggesting that
ectopic expression of the PPARg2 isoform in the liver of ob/
ob mice (see below), might contribute to the deposition of
TAGs in the liver.
Ablation of PPARg2 Induces a Lipotoxic Lipid Profile in
Adipose Tissue, Pancreatic Islets, Liver, and Skeletal
Muscle
To investigate lipotoxicity as a potential pathogenic
mechanism we used liquid chromatography/mass spectrome-
try (LC/MS) [32] to compare a broad spectrum of cellular
lipids in the adipose tissue, pancreatic islets, liver, and
Figure 2. Early Insulin Resistance in POKO Mice Independent of Body Weight
(A) Body weight and plasma glucose levels from three, four, and five-week-old female WT, ob/ob, PPARg2 KO, and POKO. *, p , 0.05; **, p , 0.01; ***, p
, 0.001 POKO versus ob/ob.
(B) Plasma glucose levels during ITT on 4-wk-old male (left) and female (right) mice on chow diet (black triangle, WT; white triangle, PPARg2 KO; black
square, ob/ob; black diamond, POKO) (n ¼ 7). *, p , 0.05; **, p , 0.01 POKO versus ob/ob.
(C) Morphological analysis of H and E-stained sections (103) in pancreas from 4-wk-old males ob/ob and POKO mice (n ¼ 5).
doi:10.1371/journal.pgen.0030064.g002
Table 2. Metabolic Parameters in 16-wk-Old Male POKO, Ob/Ob,
and WT Mice
Parameters Units WT Ob/ob POKO
Weight g 36.0 6 1.6 75.7 6 4.5 40.4 6 8.5*
Glucose fed mMol/l 10.93 6 1.45 15.27 6 2.47 54.18 6 6.5*
,***
Glucose fasted mMol/l 5.46 6 0.52 10.74 6 1.78 22.64 6 3.98*
,***
Insulin fed lg/l 1.86 6 0.49 46.63 6 8.32 9.46 6 1.84*
,***
FFA mmol/l 0.81 6 0.10 0.88 6 0.04 1.7 6 0.43
Cholesterol mmol/l 3.26 6 0.05 6.40 6 0.46 5.20 6 0.49*
,**
TAGs mmol/l 1.68 6 0.26 2.55 6 0.68 9.06 6 1.33*
,***
Adiponectin lg/ml 23.88 6 1.08 13.74 6 1.30 4.21 6 0.98*
,***
Values are mean 6 standard error of mean. n¼4/10. *, p , 0.001 POKO versus ob/ob; **,
p , 0.05 POKO versus WT; and ***, p , 0.001 POKO versus WT.
FFA, free fatty acid.
doi:10.1371/journal.pgen.0030064.t002
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PPAR gamma 2 and Lipotoxicityskeletal muscle between the POKO mouse and controls
(Protocol S1).
Adipose tissue from POKO mice has decreased TAG but
increased DAG, ceramides, and other reactive lipid species
associated with insulin resistance. Lipidomic analysis using
LC/MS identiﬁed 74 molecular species differentially present
in POKO, ob/ob, and WT mice (Protocol S1). POKO adipose
tissue had decreased short chain TAGs compared to ob/ob
adipose tissue (Protocol S1). Conversely, the concentration of
DAGs was increased in the WAT of the POKO mice compared
to ob/ob littermates. There was also an increased concen-
tration of reactive lipid species in the WAT of POKO mice
compared to that of ob/ob. The WAT of both POKO and ob/
ob mice (Protocol S1) had increased levels of two ceramide
species (with 16:0 and 24:1 fatty acid chains, respectively) and
three proinﬂammatory lysophosphatidylcholine species [33]
Figure 3. Impaired b-Cell Function and Hepatic Morphological Analyis in the POKO Mice
(A) H and E-stained sections (103) and immunohistochemical (203) analysis of insulin and glucagon in pancreas from 16-wk-old males WT, ob/ob, and
POKO mice (n ¼ 5).
(B) Insulin content of islets isolated from POKO (black bars), and ob/ob (grey bars) mice. Each data point is the mean of six samples each of five islets.
(C) Insulin secretion from islets isolated from POKO (black bars) and ob/ob (grey bars) mice in response to glucose (1, 16 mM) or glucose 16 mM þ
tolbutamide (200 lM). Data were collected from six samples each of five islets from three mice of each genotype. For each sample, insulin release was
normalised to insulin content. *, p , 0.05; **, p , 0.01; ***, p , 0.001 POKO versus ob/ob.
(D) H and E-stained sections (43) in liver from 16-wk-old males WT, ob/ob, and POKO mice (n ¼ 5).
doi:10.1371/journal.pgen.0030064.g003
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PPAR gamma 2 and Lipotoxicitycompared to WT mice. Partial least squares discriminant
analysis indicated these changes in ceramides were greater in
the POKO than ob/ob mice (Protocol S1). Sphingomyelin
(d18:1/16:0), the precursor of ceramide (d18:1/16:0) and
antioxidant ethanolamine plasmalogen (36:1) [34] were
markedly decreased in POKO and ob/ob mice (Figure 4A).
Decreased TAG and accumulation of reactive lipid species
in islets from POKO mice. Partial least-squares discriminant
analysis of lipidomic proﬁles of isolated pancreatic islets of
16-week-old mice identiﬁed 44 lipid species accumulated at
different concentrations in WT, PPARg2 KO, and POKO
mice (Protocol S1). Short chain TAGs were decreased in islets
from POKO and PPARg2 KO mice when compared to those
from WT. This was associated with up-regulation of phos-
phatidylethanolamine (36:2), down-regulation of ethanol-
amine plasmalogen (36:2), and preferential accumulation of
reactive lipid species, particularly of two ceramides (20:0 and
22:0 fatty acids) in islets from POKO mice (Figure 5A and
Protocol S1).
Decreased TAG and increased reactive lipid species in liver
of POKO mice. Multivariate analysis of lipidomic proﬁles
(192 lipid species) revealed large changes between the POKO,
PPARg2 KO, ob/ob, and WT genotypes (Protocol S1). These
included decreased levels of short and medium chain TAGs
Figure 4. Lipidomic and Gene Expression Analysis of POKO WAT
(A) Lipidomic profiling of WAT from 16-wk-old males WT, ob/ob, and POKO mice.
(B) Adipose tissue mRNA levels from different genes from 16-wk-old male WT, PPARg2 KO, ob/ob, and POKO mice (n¼6–8). *, p , 0.05; **, p ,0.01; ***,
p ,0.001 POKO versus ob/ob.
doi:10.1371/journal.pgen.0030064.g004
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PPAR gamma 2 and Lipotoxicityand DAGs (Figure 5B) in livers from POKO mice compared to
those of ob/ob mice. Livers from POKO mice also had
decrease levels of phosphatidylcholine lipid species (Protocol
S1) utilised during the formation and secretion of very low
density lipoproteins [35]. Conversely, POKO livers were
enriched in ceramides compared to ob/ob livers, which
correlated with the extent of increased levels of lysophos-
phatidylcholines in POKO and ob/ob mice (Protocol S1).
Decreased TAG and accumulation of reactive lipid species
in POKO skeletal muscle. The same lipidomic pattern of
decreased TAG and increased reactive lipid species previ-
ously observed in adipose tissue, b-cell, and liver was found to
a milder degree in the skeletal muscle of POKO mice
(Protocol S1). Brieﬂy, when compared to ob/ob skeletal
muscle, POKO skeletal muscle showed a decrease in very
short-chain fatty acid TAGs and a slight decrease in levels of
medium and long chain TAGs (Protocol S1). The skeletal
muscle of POKO mice also had increased reactive lipids
including ceramide (d18:1/18:0), DAGs, lysophosphatidylcho-
lines, and sphingomyelins (precursors of ceramides) when
compared to that of ob/ob mice.
Transcriptomic Analysis in POKO Mice Correlates with
Lipidomic Changes
Given the lipotoxic proﬁles identiﬁed in the POKO mouse,
we hypothesised changes in the expression of metabolic genes
directly related to PPARg2 ablation and also compensatory
changes in genes associated with cellular stress (Table S4).
Gene expression analysis in WAT. Target genes of PPARg
such as Glut4, adipsin, aP2, and adiponectin were decreased to a
larger extent in the WAT of ﬁve- and 16-week-old POKO
mice than in PPARg2 KO mice (Figure S1 and Figure 4B). At
ﬁve weeks of age, when differences in body fat between
female WT, ob/ob, and POKO mice are only starting to
Figure 5. Lipidomic and Gene Expression Analysis in Islets and Liver from POKO Mice
Lipidomic profiling of islets (A) and liver (B) from 16-wk-old males WT, PPARg2 KO, ob/ob, and POKO mice. TG, TAGs; DAGs, diacylglycerols; SM,
sphingomyelins. (C) Liver gene expression from 16-wk-old male WT, ob/ob, PPARg2 KO, and POKO mice fed chow (n¼6–8). *, p , 0.05; **, p, ,0.01; ***,
p ,0.001 POKO versus ob/ob; ###, p , 0.001 POKO versus WT; zzz,p, 0.001 ob/ob versus WT.
doi:10.1371/journal.pgen.0030064.g005
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mRNA levels were similar in WT and ob/ob mice, yet were
markedly decreased in POKO mice. As the ob/ob mice aged
(16 wk) and became obese and insulin resistant, the
expression pattern of these PPARg targets in the WAT of
ob/ob mice became similar to that of the POKO mice.
Results from the lipidomic analysis suggested major
changes in the expression of genes involved in lipid
metabolism (Figure 4B). Expression of stearoyl-coenzyme A
desaturase 1 (Scd1) and sterol regulatory element-binding
protein-1c (SREBP1c) were signiﬁcantly lower in WAT from
POKO mice compared to ob/ob mice. Furthermore, the
decrease in TAGs and increased DAGs correlated with
decreased expression of DAG acyltransferase 2, a key enzyme
catalysing the ﬁnal step in TAG synthesis, in the WAT of
POKO mice compared with WAT from ob/ob mice. Again
supporting the lipidomic proﬁle, the expression of hormone-
sensitive lipase, a rate-limiting enzyme for hydrolysis of
diacylglycerides, was decreased in the WAT of POKO,
PPARg2 KO, and ob/ob mice compared with WT mice, with
the lowest levels observed in the POKO mice. Adipose
triglyceride lipase levels were decreased in ob/ob and POKO
compared with WT and PPARg2 KO mice, but without
signiﬁcant differences between ob/ob and POKO mice.
Oxidative stress has recently been suggested as a common
mechanism of insulin resistance. Adipose tissue from POKO
mice had increased oxidative stress compared to that of ob/ob
mice as indicated by decreased gene expression levels of
extracellular CuZn-superoxide dismutase, disruption of the
glutathione pathway as indicated by decreased levels of
gluthatione synthase, and increased levels of peroxidase and
several gluthatione transferases (Table S2). We examined
macrophage inﬁltration of adipose tissue as a potential
marker of inﬂammation associated insulin resistance. Ex-
pression of CD68 and F4/80, both macrophage markers, was
increased in the WAT of both POKO and ob/ob mice
compared with WT and PPARg2 KO mice (Figure 4B).
However their expression levels were lower in the POKO
mice than the ob/ob mice suggesting that macrophage
inﬁltration was not directly related to the exacerbated insulin
resistance of the POKO mouse compared to the ob/ob mouse.
Gene expression in the POKO liver. Reduced hepatic
steatosis accompanied by altered lipid proﬁles suggested that
lack of hepatic ectopic expression of PPARg2 might be
affecting lipid storage and metabolism in the liver of the
POKO mice. Expression of genes involved in lipid metabo-
lism in liver (Figure 5C) revealed that, proportional to the
accumulation of TAGs in the liver, fatty acid synthase, Scd1,
and the fatty acid translocase (FAT/CD36) were increased in
ob/ob and POKO livers compared to WT mice and were
signiﬁcantly decreased in liver from POKO mice compared
with liver from ob/ob mice. Other lipogenic PPARg target
genes such as Lpl were also decreased in the POKO liver
compared to the ob/ob mice. The ob/ob mice also had a
compensatory increase in the expression of genes involved in
b-oxidation (e.g., Pparg, Lcad, Aox, Cpt1, and Ucp2). Interest-
ingly expression of these pro-oxidative genes was decreased
in the liver of POKO mice when compared to that of ob/ob
mice suggesting PPARg2 may contribute to their regulation
[36].
Although b-cell failure could account for the severe
hyperglycaemia observed in the POKO genotype, hepatic
gluconeogenesis function might be affected. We observed a
robust up-regulation of PPARg coactivator 1 alpha (PPARG-
C1a, also known as PGC1a) expression in the POKO liver
compared with the WT and ob/ob mice. PPARGC1a is up-
regulated in fasting and is thought to induce gluconeogenesis
[37]. In parallel with the increase in PPARGC1a, microarray
analysis revealed increased mRNA levels of the progluconeo-
genic genes phosphoenolpyruvate carboxykinase 1 (Pepck1)
and glucose-6-phosphatase (G6pc) in the livers of POKO mice
when compared to those of ob/ob mice (Table S2), suggesting
hepatic gluconeogenesis may contribute to the hyperglycae-
mia observed in POKO mice.
Gene expression analysis in skeletal muscle of POKO mice.
In 16-week-old POKO-mice skeletal muscle we observed
down-regulation of Srebp1c and Ppargc1a and up-regulation of
Ucp2 expression in skeletal muscle from POKO mice
compared to that of WT mice. Similarly, expression of Lpl
and Scd1 was down-regulated in the skeletal muscle of POKO
mice when compared with that from ob/ob mice (Figure S5;
Table S2). Gene set enrichment analysis of microarray data
showed decreased expression of oxidative phosphorylation
and mitochondrial components including electron transport
chain complex components, in skeletal muscle from POKO
mice when compared with that from ob/ob mice (Table S3).
Discussion
The link between obesity, insulin resistance, and diabetes
while epidemiologically very clear is still not properly
understood at a mechanistic level. An emerging concept is
that the absolute amount of fat stored may be less important
than the remaining storage capacity of the adipose tissue.
Here we show that the PPARg2 isoform may be an important
factor controlling obesity-induced comorbidities through two
mechanisms: (a) by regulating nutritionally induced adipose
tissue expandability and (b) when de novo expressed in
nonadipose tissues, by allowing the storage of energy in the
form of relatively harmless TAG species.
Previously we described the metabolic phenotype of the
adult PPARg2 KO mouse [2], characterised by mild insulin
resistance observed only in males. Given the greater
adipogenic potency of PPARg2 compared with PPARg1 in
vitro, we expected PPARg2 KO mice to have many more
severe defects in adipose tissue than we observed, and
therefore insulin sensitivity. As PPARg2 is the PPARg isoform
regulated in response to nutrition and obesity [17–20], we
hypothesised that PPARg2 would only become essential for
adipose tissue function in the face of positive energy balance.
The metabolic challenge we opted for was PPARg2 ablation
in the obese (ob/ob) background (PPARg2
 /  Lep
ob/Lep
ob,
POKO mouse). The POKO mouse had severely decreased
body-fat mass due to impaired adipose tissue expandability.
Despite eating as much as an ob/ob mouse and expending a
similar amount of energy, the POKO mouse was unable to
store fat efﬁciently in its adipose tissue. This mismatch
between increased energy availability and lack of adipose
tissue expandability lead to a global metabolic failure
characterised by severe insulin resistance, b-cell failure, and
dyslipidaemia.
The observation of reduced fat mass and increased insulin
resistance in the POKO mouse compared to the ob/ob mouse
strongly supports two of our hypotheses. First, we hypoth-
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overnutrition, but it is not required to make adipocytes
during development. This is reﬂected by similar expression of
aP2, a late marker of adipocyte differentiation, in POKO and
ob/ob mice. The absence of small adipocytes was markedly
different to other forms of lipodystrophy [38,39]. Addition-
ally, and again in contrast with other lipodystrophic models
that have markedly less adipose tissue than WT controls [38–
40], the POKO mice had a percentage body fat that was
similar (only 4% more) to WT and PPARg2 KO mice, as
opposed to ob/ob mice, which had 40% fat as a proportion of
body mass. This suggests that the remaining PPARg1 isoform
is sufﬁcient to support development of adipose tissue and fat
deposition requirements of a lean mouse model. However,
under conditions of positive energy balance, adipose tissue
expandability mainly relies on the PPARg2 isoform. This idea
is also suggested by the studies in heterozygous mice
harbouring the murine equivalent of the human mutation
(P465L) in PPARg on an ob/ob background [41]. These mice
were able to accumulate fat and become obese even though
showing a body mass 14% lower than ob/ob controls. In
humans there is also evidence for a role for PPARg2. We have
observed that metabolically healthy, nondiabetic, morbidly
obese individuals have elevated levels of PPARg2 in their
adipose tissue when compared to lean individuals [19]. Our
second hypothesis, that the mismatch between energy
availability and adipose tissue expandability is more impor-
tant than fat mass itself as a predictor of insulin resistance, is
also supported by our data. In fact the ob/ob mouse is much
more obese than the POKO mouse but is much less insulin
resistant. Furthermore, the POKO mice were already more
insulin resistant than the ob/ob mice by the age of four weeks,
with very low levels of GLUT4 in adipose tissue, before large
differences in body weight developed, suggesting that the
bioenergetic mismatch rather than the total amount of fat
stored is important for the development of insulin resistance.
Although we hypothesised that the POKO mice would
become insulin resistant, the degree of hyperglycaemia in
these animals was in excess of what we expected. We found
that the normal adaptive response of b-cells to insulin
resistance did not occur in the POKO mice as indicated by
the pathological changes observed by histology and the lack
of b-cell hypertrophy. Although it has been shown that
genetic background can affect the ability of ob/ob mice to
undergo b-cell hypertrophy [42,43], we found that the ob/ob
controls on our mixed 129Sv 3 C57BL/6J background
underwent adaptive b-cell hyperplasia and hypertrophy,
suggesting that the lack of PPARg2 was responsible for the
failure of the POKO b-cells to adapt to insulin resistance.
Interestingly the mass of pancreatic islets in POKO mice
remained similar to the noninsulin resistant WT and PPARg2
KO mice. Furthermore, these defects in POKO b-cells did not
appear to be the result of a developmental defect, as new
born and four-week-old mice had morphologically normal
islets.
The severe b-cell phenotype of the POKO mouse contrasts
with the absence of hyperglycaemia observed in the pancre-
atic b-cell speciﬁc PPARg KO mouse [30]. However it should
be kept in mind that in the b-cell speciﬁc PPARg KO mouse,
the expression of PPARg and the lipid storage capacity of
other tissues, most importantly adipose tissue, were not
affected, and that insulin sensitivity was only mildly affected
by high fat feeding in these mice when compared to the
severe insulin resistance observed in POKO mice. Therefore
the challenge to the pancreatic b-cells in this model was
milder than in POKO mice. This is a clear example of how
tissue-speciﬁc genetic manipulations are not always the best
approach to understand the physiology of an organ in the
context of the global energy homeostasis. The potential
importance of the de novo expression of PPARg2 isoform in
b-cells is also supported by the observation that humans
harbouring the Pro12Ala mutation in PPARg2, a mutation
that is located in the g2 isoform and makes PPARg2 less
active, has only been associated with insulin deﬁciency and
disease severity in obese individuals with type 2 diabetes [44].
The liver of the POKO mouse also displayed an unusual
phenotype. We expected the POKO mice to have worse
hepatosteatosis with increased triglyceride deposition in liver
compared to ob/ob mice, because the POKO mice could not
store fat in adipose tissue. However POKO mice had less
hepatosteatosis than ob/ob mice suggesting that the PPARg2
isoform may directly contribute to facilitate triglyceride
deposition in the liver.
A common mechanistic link for the phenotypes observed
in the POKO liver and b-cell was not immediately obvious. To
try to determine the role of PPARg2 in these locations we
performed lipidomic and gene expression analyses of the
adipose tissue, pancreatic islet, liver, and skeletal muscle of
the POKO mouse. The lipid pattern of adipose tissue from
POKO mice was characterised by decreased TAGs and
increased DAGs in parallel with decreased gene expression
of DGAT2, hormone-sensitive lipase, and adipose triglyceride
lipase. This decrease in TAGs in the POKO adipose tissue was
associated with increased levels of reactive lipid species and a
gene expression proﬁle suggestive of increased oxidative
stress [45–49]. Although it has been described that oxidative
stress and insulin resistance may be related to inﬁltration of
adipose tissue by macrophages, resulting in a chronic state of
inﬂammation [50–52], we did not observe increased macro-
phage inﬁltration in the adipose tissue of POKO mice
compared to that of ob/ob mice.
Lipidomic analysis of POKO derived islets also showed
decreased levels of triacyl and DAGs and increased levels of
ceramides, suggesting that PPARg2 may contribute to
increasing the lipid-buffering capacity of b-cells by promot-
ing formation of TAGs and thus preventing lipotoxic insults.
Liver and skeletal muscle lipidomics also showed reduced
TAG and increased formation of reactive lipid species such as
ceramides and lysophosphatidylcholines in POKO mice
compared to ob/ob mice. This lipid proﬁle was associated
with impaired expression of pathways controlling de novo
lipogenesis, transport of fatty acids, and beta oxidation in the
POKO mice compared with the ob/ob mice. Of interest,
Ppargc1a and other gluconeogenic genes were induced in the
liver of POKO mice compared to that of ob/ob mice,
suggesting a potential mechanism contributing to marked
hyperglycaemia in POKO mice [53,54].
Overall, our lipidomic studies identify a remarkably
similar pattern of changes in lipid species in the four tissues
studied. The reduced adipose tissue mass and hepatosteatosis
in the POKO mouse compared to the ob/ob mouse is
explained by reduced levels of mature TAG in the POKO
mouse. Similarly, ablation of PPARg2 resulted in accumu-
lation of reactive lipid species implicated in causing insulin
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organs involved in whole-organism glucose metabolism.
These results indicate that expression of PPARg2 in the
pancreas, liver, and muscle of the ob/ob mouse may be
performing a protective role, by increasing the capacity of
these organs to buffer toxic lipid species by allowing
accumulation of relatively harmless TAGs. The importance
of this peripheral antilipotoxic role of PPARg2 becomes
more evident if we consider that POKO and ob/ob mice are
under the same degree of positive energy balance as
determined by similar food intake, locomotor activity, and
energy expenditure, that both models lack leptin, and that
the only difference between ob/ob and POKO mice is the
presence or absence of PPARg2. Given the decreased
adipose tissue expandability of the POKO mice compared
to ob/ob, it was anticipated that, as in the liver, muscle, or b-
cells of lipodistrophic mice, the POKO mouse would
accumulate more fat than the ob/ob. However, our results
clearly indicate that mice lacking PPARg2, despite massive
nutrient availability, are unable to deposit TAG in periph-
eral tissues and instead accumulate reactive lipid species in
these organs. Therefore the pathologies of the liver and b-
cell observed in the POKO mouse may be a result of a
common lipotoxic insult facilitated by the absence of
PPARg2 (Figure 6).
In summary, in this study we provide new insights into the
physiological relevance of the PPARg2 isoform and identify
adipose tissue expandability as an important determinant of
metabolic complications. Ablation of PPARg2 decreases
adipose tissue expandability, but its pathophysiological
effects only become relevant in the context of a mismatch
between energy availability and adipose tissue expansion. We
show that PPARg2 also plays protective role when expressed
de novo in peripheral organs by increasing their capacity to
buffer toxic lipids. Ablation of PPARg2 under conditions of
positive energy balance determined by absence of leptin
produced early development of severe insulin resistance, b-
cell failure, diabetes, and hyperlipidaemia. Extrapolation of
this model to humans may suggest that normal to overweight
individuals with positive energy balance and inappropriately
severe manifestations of the MS may have a defect in PPARg2
and/or alternative mechanisms that control adipose tissue
expandability.
Figure 6. Storage of Lipids—Antilipotoxic Role of PPARg2
Antilipotoxic role of PPARg2 mediated by (a) expansion of adipose tissue and facilitation of triglyceride deposition and (b) facilitating deposition of fat
in liver, skeletal muscle, and pancreas in the form of TAG. Ob/Ob mice can induce PPARg2 expression in liver, muscle, and b-cell, facilitating deposition
of excess of energy in these organs in the form of TAG. Absence of inducibility of PPARg2 in POKO mouse liver, muscle, and b-cells results in increased
deposition of reactive lipid species and decreased TAG, leading to marked insulin resistance and b-cell failure.
doi:10.1371/journal.pgen.0030064.g006
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Generation of mice homozygous for PPARg2 KO and leptin
deﬁciency (ob/ob). Mice heterozygous for a disruption in exon B1 of
PPARg2 on a 129Sv background (PPARg2
þ/ ) [2] were crossed with
heterozygous ob/ob (Lep
ob/Lep
þ) mice on a C57Bl/6 background to
obtain mice heterozygous for both the PPARg2 ablation and the
leptin point mutation (PPARg2
þ/  Lep
ob/Lep
þ). These mice were
crossed to obtain the four experimental genotypes: WT (PPARg2
þ/þ
Lep
þ/Lep
þ), PPARg2 KO (PPARg2
 /  Lep
þ/Lep
þ), ob/ob (PPARg2
þ/þ
Lep
ob/Lep
ob), and POKO (PPARg2
 /  Lep
ob/Lep
ob). Genotyping for
deletion of PPARg2 and the point mutation in the ob gene was
performed by PCR using standard protocols [2,55].
Animal care. Animals were housed at a density of four animals per
cage in a temperature-controlled room (20–22 8C) with 12-h light/
dark cycles. Food and water were available ad libitum unless noted.
All animal protocols used in this study were approved by the UK
Home Ofﬁce and the University of Cambridge.
Blood and urine biochemistry, food intake, and body composition
analysis. Mice of the four experimental genotypes were placed at
weaning (three weeks of age) on a normal chow diet (10% of calories
derived from fat; D12450B, Research Diets, http://www.researchdiets.
com). Enzymatic assay kits were used for determination of plasma
FFAs (Roche, http://www.roche.com) and TAGs (Sigma-Aldrich, http://
www.sigmaaldrich.com). Elisa kits were used for measurements of
leptin (R & D Systems, http://www.rndsystems.com), insulin (DRG
Diagnostics International Limited, http://www.drg-international.com),
and adiponectin (B-Bridge International, http://www.b-bridge.com)
according to manufacturers’ instructions. Dual-energy X-ray absorp-
tiometry (DEXA, Lunar Corporation, http://www.lunarcorp.com) was
used to measure body composition; glucose in blood and in urine and
food intake were monitored in the four experimental genotypes as
previously shown [2].
Oxygen consumption, water intake, and locomotor activity. Oxy-
gen was measured using an eight-chamber open-circuit oxygen-
monitoring system attached to and sampled from the chambers of a
Comprehensive Laboratory Animal Monitoring System (CLAMS;
Columbus Instruments, http://www.colinst.com). Water consumed
was also measured using CLAMS. Mice were housed individually in
specially built Plexiglass cages maintained at 22 8C under an
alternating 12:12-h light-dark cycle (light period 08:00–20:00). Sample
air was sequentially passed through oxygen (O2) and carbon dioxide
(CO2) sensors (Columbus Instruments) for determination of O2 and
CO2 content. Mice were acclimatized to monitoring cages for 72 h
before data collection. Mice were weighed before each trial.
Ambulatory activity of individually housed mice was evaluated using
an eight-cage rack OPTO-M3 Sensor system (Columbus Instruments).
Cumulative ambulatory activity counts were recorded every 5 min
throughout the light and dark cycles.
Calculations of energy lost in urine. Energy lost in urine was
calculated accordingly as previously shown before [56] using the
following calculations:
Energy lost in urine kJ/day ¼ (glucose in urine [mMol/l]/1,000) 3
molecular weight glucose 3 (water intake [ml/day]/1,000) 3 E
densitycarb; E densitycarb¼energy density related to oxidations within
the body for carbohydrates as glucose ¼ 15.76 kJ/g.
RNA preparation and real-time quantitative RT-PCR. Total RNA
was isolated from islets and tissues samples according to the
manufacturer’s instructions (RNAeasy kit, Qiagen, http://www.
qiagen.com) and STAT60 (Tel-Test, http://www.isotexdiagnostics.
com/tel-test.html). Real-time quantitative PCR was performed using
a TaqMan 7900 (Applied Biosystems, http://www.appliedbiosystems.
com) according to standard protocols.
Western blot analyses. The tissue samples (40 lg) were subjected to
SDS-PAGE on 8% polyacrylamide gels. Proteins were then electro-
phoretically transferred to polyvinylidene diﬂuoride ﬁlters. After
transferring, the ﬁlters were blocked with 5% nonfat dry milk in TBS-
Tween 20 followed by incubation with primary GLUT4 and
extracellular signal-regulated kinase 1/2 (ERK1/2) antibodies (Prom-
ega, http://www.promega.com) overnight. The bands were quantiﬁed
by scanning densitometry.
Light microscopy and immunohistochemcal analysis. Tissue sam-
ples for morphological and immunohistochemcal analysis were
preparedaccordingtopublishedprotocols[2].Morphometricanalyses
of adipose tissue and pancreas sections were acquired using a digital
camera and microscope (Olympus BX41, http://www.olympus.com),
and cell areas were measured using AnalySIS software (Soft Imaging
System, http://www.soft-imaging.net). For adipose tissue, two ﬁelds
from each section were analysed to obtain the mean cell-area per
animal (n ¼ 5 per genotype). The Computer Assisted Stereology
Toolbox (CAST) 2.0 system from Olympus was used to perform all
measurements in the pancreas according to published protocols
[57].
Isolation and culture of pancreatic islets. The pancreas was
injected via the bile duct with cold Hank’s solution containing
0.4% (w/v) liberase (Roche). The pancreas was removed, digested for
15–30 min, and islets collected by handpicking. Isolated islets were
cultured overnight in h-cell medium (SBMI 06, hcell technology,
http://www.hcell.com) at 37 8Ci n5 %C O 2 in air. Islets were used the
day after isolation for insulin secretion studies or RNA extraction.
Insulin secretion studies. Insulin secretion from isolated islets (ﬁve
islets/well) was measured during 1-hr static incubations in Krebs—
Ringer Buffer containing either 1 mM glucose, 16.7 mM glucose, or
16.7 mM glucose plus 200 lM tolbutamide in DMSO. The super-
natants were assayed for insulin. Insulin content was extracted using
95:5 ethanol/acetic acid. Insulin was measured using a Mouse Insulin
ELISA kit (Mercodia, http://www.mercodia.com). Islets were isolated
from three mice of each genotype for these experiments. Thus, the
data are the mean of three separate experiments, in which data were
collected for each test solution from six samples each of ﬁve islets.
For each sample, insulin release was normalised to insulin content.
ITT. ITTs on four-week-old mice were performed as previously
published [58].
Lipid proﬁling. For WAT and muscle, the tissue sample (50 mg) was
homogenized with 0.15 M sodium chloride (300 ll), and the lipids
were extracted with 2 ml of chloroform: methanol (2:1) and used for
LC/MS as previously described [2].
For liver and islets, an aliquot (20 ll for liver or 10 ll for islets) of
an internal standard mixture (11 reference compounds at concen-
tration level 8–10 lg/ml), 50 ll of 0.15 M sodium chloride (for liver),
and chloroform:methanol (2:1) (200 ll for liver or 90 ll for islets) was
added to the tissue sample (20–30 mg). The sample was homogenized,
vortexed (2 min for liver or 15 s for islets), let to stand (1 h for liver,
20 min for islets), and centrifuged at 10,000 RPM for 3 min. From the
separated lower phase, an aliquot was mixed with 10 ll of a labelled
standard mixture (three stable isotope-labelled reference compounds
at concentration level 9–11 lg/ml), and 0.5–1.0 ll injection was used
for LC/MS analysis.
Total lipid extracts were analysed on a Waters Q-Tof Premier mass
spectrometer (http://www.waters.com) combined with an Acquity
Ultra Performance LC (UPLC). The column, which was kept at 50
8C, was an Acquity UPLC BEH C18 10350 mm with 1.7 lm particles.
The binary solvent system (ﬂow rate 0.200 ml/min) included A, water
(1% 1 M NH4Ac, 0.1% HCOOH), and B, LC/MS grade (Rathburn,
http://www.rathburn.co.uk) acetonitrile/isopropanol (5:2, 1% 1 M
NH4Ac, 0.1% HCOOH). The gradient started from 65% A/35% B,
reached 100% B in 6 min, and remained there for the next 7 min. The
total run time per sample, including a 5 min re-equilibration step,
was 18 min. The temperature of the sample organizer was set at 10 8C.
Mass spectrometry was carried out on Q-Tof Premier (Waters) run
in ESIþ mode. The data were collected over the mass range of m/z
300–1,200 with scan duration of 0.2 s. The source temperature was set
at 120 8C, and nitrogen was used as desolvation gas (800 l/h) at 250 8C.
The voltages of the sampling cone and capillary were 39 V and 3.2 kV,
respectively. Reserpine (50 lg/l) was used as the lock spray reference
compound (5 ll/min; 10 s-scan frequency).
Data processing was performed using the MZmine software [59].
Identiﬁcation was performed based on an internal reference database
of lipid species, or alternatively utilizing the tandem mass spectrom-
etry. The statistical analyses were performed using Matlab (Math-
works, http://www.mathworks.com) and the Matlab library PLS
Toolbox (Eigenvector Research, http://www.eigenvector.com).
Tandem mass spectrometry was used for the identiﬁcation of
selected lipid species. MS/MS runs were performed by using ESIþ
mode, collision energy ramp from 15–30 V, and mass range starting
from m/z 150. The other conditions were as shown in the Protocol S1.
Statistics. Results were expressed as mean 6 standard error of
mean. Statistical analysis was performed using a two-tailed unpaired
t-test between appropriate pairs of groups, and signiﬁcance declared
if p-values were less than 0.05.
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